KR102897673B1 - 항염증 및 성장 촉진 활성을 갖는 데스아세틸글루코사민 무라밀 디펩티드의 친지성 거울상이성질체 - Google Patents

항염증 및 성장 촉진 활성을 갖는 데스아세틸글루코사민 무라밀 디펩티드의 친지성 거울상이성질체

Info

Publication number
KR102897673B1
KR102897673B1 KR1020227036717A KR20227036717A KR102897673B1 KR 102897673 B1 KR102897673 B1 KR 102897673B1 KR 1020227036717 A KR1020227036717 A KR 1020227036717A KR 20227036717 A KR20227036717 A KR 20227036717A KR 102897673 B1 KR102897673 B1 KR 102897673B1
Authority
KR
South Korea
Prior art keywords
delete delete
substituted
oligopeptide
composition
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227036717A
Other languages
English (en)
Korean (ko)
Other versions
KR20220158773A (ko
Inventor
호레이스 디스톤 주니어 날레
베른하르드 칼텐버크
Original Assignee
뉴트리버트 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 뉴트리버트 인크. filed Critical 뉴트리버트 인크.
Publication of KR20220158773A publication Critical patent/KR20220158773A/ko
Application granted granted Critical
Publication of KR102897673B1 publication Critical patent/KR102897673B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020227036717A 2020-03-26 2021-03-25 항염증 및 성장 촉진 활성을 갖는 데스아세틸글루코사민 무라밀 디펩티드의 친지성 거울상이성질체 Active KR102897673B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063000364P 2020-03-26 2020-03-26
US63/000,364 2020-03-26
PCT/US2021/024142 WO2021195372A1 (en) 2020-03-26 2021-03-25 Lipophilic enantiomers of desacetylglucosamine muramyl dipeptide with anti-inflammatory and growth promoting activity

Publications (2)

Publication Number Publication Date
KR20220158773A KR20220158773A (ko) 2022-12-01
KR102897673B1 true KR102897673B1 (ko) 2025-12-09

Family

ID=77892334

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227036717A Active KR102897673B1 (ko) 2020-03-26 2021-03-25 항염증 및 성장 촉진 활성을 갖는 데스아세틸글루코사민 무라밀 디펩티드의 친지성 거울상이성질체

Country Status (13)

Country Link
US (1) US12492222B2 (enExample)
EP (1) EP4126040B1 (enExample)
JP (1) JP7667177B2 (enExample)
KR (1) KR102897673B1 (enExample)
CN (1) CN115605226A (enExample)
AU (1) AU2021241625B2 (enExample)
BR (1) BR112022019202A2 (enExample)
CA (1) CA3172936A1 (enExample)
ES (1) ES3014076T3 (enExample)
MX (1) MX2022011751A (enExample)
PL (1) PL4126040T3 (enExample)
WO (1) WO2021195372A1 (enExample)
ZA (1) ZA202210586B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3929293A3 (en) 2015-04-03 2022-03-16 University Of Massachusetts Fully stabilized asymmetric sirna
WO2017030973A1 (en) 2015-08-14 2017-02-23 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
WO2017132669A1 (en) 2016-01-31 2017-08-03 University Of Massachusetts Branched oligonucleotides
WO2018237245A1 (en) 2017-06-23 2018-12-27 University Of Massachusetts TWO TAIL SELF-ADMINISTRATION SIRNA AND ASSOCIATED METHODS
BR112021002440A2 (pt) 2018-08-10 2021-05-04 University Of Massachusetts oligonucleotídeos modificados visando snps
WO2020041769A1 (en) 2018-08-23 2020-02-27 University Of Massachusetts O-methyl rich fully stabilized oligonucleotides
CN113614232A (zh) 2019-01-18 2021-11-05 马萨诸塞大学 动态药代动力学修饰锚
EP3946369A4 (en) 2019-03-26 2023-10-18 University Of Massachusetts MODIFIED OLIGONUCLEOTIDES WITH INCREASED STABILITY
KR20220047989A (ko) 2019-08-09 2022-04-19 유니버시티 오브 매사추세츠 Snp를 표적화하는 화학적으로 변형된 올리고뉴클레오타이드
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
AU2021244600A1 (en) 2020-03-26 2022-11-03 University Of Massachusetts Synthesis of modified oligonucleotides with increased stability
CN115605226A (zh) 2020-03-26 2023-01-13 纽特莱特公司（Us） 具有抗炎和生长促进活性的去乙酰基葡糖胺胞壁酰二肽的亲脂对映异构体
CA3174079A1 (en) 2020-05-26 2021-12-02 Anastasia Khvorova Synthetic oligonucleotides having regions of block and cluster modifications
WO2024102639A1 (en) * 2022-11-08 2024-05-16 The Scripps Research Institute N-arylpyrazole nod2 agonists as promoters of immune checkpoint inhibitor therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016008946A1 (en) 2014-07-16 2016-01-21 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Novel compounds
US20180371023A1 (en) 2015-12-10 2018-12-27 Bharat Biotech International Limited Novel muramyl peptide derivative compound, synthesis and uses thereof
US20190125873A1 (en) 2017-10-28 2019-05-02 Far Eastern Memorial Hospital Glucosamine peptide compounds for treating liver metabolic disorders

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2428051A1 (fr) * 1978-06-05 1980-01-04 Anvar Nouveaux composes du type muramyl-peptide et medicaments les contenant
SI9011830B (sl) 1990-09-27 1999-12-31 Univerza V Ljubljani, Fakulteta Za Farmacijo Novi N-acildipeptidi, postopki za njihovo pripravo in farmacevtski pripravki, ki jih vsebujejo
JPH0655107B2 (ja) 1991-03-13 1994-07-27 全国農業協同組合連合会 家畜，家禽，および魚介類用の抗仮性狂犬病ならびに抗病性飼料および飼料用添加物
WO1993013791A1 (en) 1992-01-20 1993-07-22 Peptech (Uk) Limited Use of muramyl peptides for enhancing animal production
MX9301789A (es) 1992-04-03 1993-10-01 Iaf Biochem Int Nuevos oligopeptidos lipofilicos con actividad inmunomoduladora.
CN1162920A (zh) * 1994-09-21 1997-10-22 英国佩普技术有限公司 胞壁酰肽化合物的应用
US5976580A (en) 1995-06-07 1999-11-02 Novus International, Inc. Nutrient formulation and process for enhancing the health, livability, cumulative weight gain or feed efficiency in poultry and other animals
GB9618673D0 (en) * 1996-09-06 1996-10-16 Peptech Uk Ltd The use of muramyl peptides
RU2375047C2 (ru) 2004-03-26 2009-12-10 Лек Фармасьютиклз Д.Д. Фармацевтическая лекарственная форма, устойчивая к действию желудочного сока, включающая n-(2-(2-фталимидоэтокси)ацетил)-l-аланил-d-глутаминовую кислоту (lk 423)
CA2666814A1 (en) 2006-08-21 2008-05-29 United Therapeutics Corporation Combination therapy for treatment of viral infections
WO2008070564A1 (en) 2006-12-01 2008-06-12 The Government Of The U.S.A, As Represented By The Secretary, Departmentof Health And Human Services Uses of muramyl dipeptide (mdp) for treating inflammation
KR20100059863A (ko) 2007-09-11 2010-06-04 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드 티모신 베타 ４ 단독 또는 세크로핀 ａ와의 배합물의 용도
CN101918001B (zh) 2007-12-06 2016-11-16 英特威国际有限公司 使用醋酸美仑孕酮和齐帕特罗或其盐的联合治疗
CN101756026A (zh) 2008-12-11 2010-06-30 天津瑞贝特科技发展有限公司 增强虾、蟹硬壳速度的营养组合物及其制备方法、应用
DE102009002044A1 (de) 2009-03-31 2010-10-07 Evonik Degussa Gmbh Dipeptide als Futtermitteladditive
BR112013027845A2 (pt) 2011-05-18 2017-01-03 Ajinomoto Kk Imunoestimulante, ração, método para produzir um imunoestimulante, e, método para imunoestimulação
CN102578414B (zh) 2012-02-23 2014-01-01 青岛绿曼生物工程有限公司 促进猪生长育肥、提高免疫力的复方蜂胶饲料添加剂及其制备方法
WO2013172517A1 (ko) 2012-05-16 2013-11-21 서울대학교산학협력단 뮤라밀-다이펩타이드를 포함하는 골소실 예방, 골재생 또는 골형성 촉진용 약학 조성물
WO2017068149A1 (en) 2015-10-21 2017-04-27 Cysal Gmbh Aspartyl-dipeptides for aquaculture
CN109562158A (zh) 2016-06-23 2019-04-02 纽特莱特公司 在动物中促进生长和提高饲料转化率的方法
WO2020019128A1 (zh) 2018-07-23 2020-01-30 深圳市健元医药科技有限公司 丙氨酸—赖氨酸—谷氨酸三肽衍生物及其应用
CN115605226A (zh) 2020-03-26 2023-01-13 纽特莱特公司（Us） 具有抗炎和生长促进活性的去乙酰基葡糖胺胞壁酰二肽的亲脂对映异构体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016008946A1 (en) 2014-07-16 2016-01-21 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Novel compounds
US20180371023A1 (en) 2015-12-10 2018-12-27 Bharat Biotech International Limited Novel muramyl peptide derivative compound, synthesis and uses thereof
US20190125873A1 (en) 2017-10-28 2019-05-02 Far Eastern Memorial Hospital Glucosamine peptide compounds for treating liver metabolic disorders

Also Published As

Publication number Publication date
NZ792610A (en) 2025-07-25
ZA202210586B (en) 2023-05-31
JP7667177B2 (ja) 2025-04-22
AU2021241625B2 (en) 2025-04-24
AU2021241625A1 (en) 2022-11-10
JP2023518973A (ja) 2023-05-09
EP4126040A4 (en) 2024-04-24
EP4126040A1 (en) 2023-02-08
US20230174577A1 (en) 2023-06-08
WO2021195372A1 (en) 2021-09-30
EP4126040C0 (en) 2025-02-19
ES3014076T3 (en) 2025-04-16
BR112022019202A2 (pt) 2022-11-08
PL4126040T3 (pl) 2025-04-28
KR20220158773A (ko) 2022-12-01
CA3172936A1 (en) 2021-09-30
EP4126040B1 (en) 2025-02-19
CN115605226A (zh) 2023-01-13
US12492222B2 (en) 2025-12-09
MX2022011751A (es) 2022-12-02

Similar Documents

Publication Publication Date Title
JP7667177B2 (ja) 抗炎症性および成長促進活性を有するデスアセチルグルコサミンムラミルジペプチドの親油性エナンチオマー
US10626139B2 (en) Cationic steroidal antimicrobial compounds
JP4151765B2 (ja) 免疫調節活性を有する新規な置換プリニル誘導体
US11286276B2 (en) Cationic steroidal antimicrobials
RU2669800C2 (ru) Способы лечения воспаления, аутоиммунных расстройств и боли
JP5000848B2 (ja) グレリン含有医薬組成物
JP4754731B2 (ja) 豚成育促進剤及び豚成育促進方法
US20230310444A1 (en) Compositions and methods for treating diseases and disorders
US20190191740A1 (en) Methods to Promote Growth and Improve Feed Conversion in Animals
CN106377757A (zh) 含氧碳氢衍生物作为多粘菌素的协同增效剂的应用
FR2630649A1 (fr) Sels d'addition d'acides de derives n-acyles de la taurine ou de la glycine, leur preparation et leur utilisation
JP3247380B2 (ja) 非経口投与用の安定化ソマトトロピン
EP1480673A1 (en) A bioadhesive agent
JPH01311093A (ja) 置換ｎ―グリコシルアミド類
WO2025006896A1 (en) Low dose muramyl dipeptide analogue-containing compositions and methods of using same for immunoprotection
EA001530B1 (ru) Способ лечения или предотвращения бактериальной респираторной или кишечной инфекции домашнего скота
EP3838347B1 (en) Evernimicin for treating diseases like necrotic enteritis
US5503830A (en) Compounds having immunostimulating activity and methods of use thereof
JP2025520449A (ja) Ｘ－ａｌｄ治療のための甲状腺ベータ作動薬投与計画
EP0394684A1 (en) Immunopotentiator and spergualin-related compound therefor
WO2025244084A1 (ja) ＰＰＡＲγ活性化により処置し得る状態の処置剤
CN122055148A (zh) 用于治疗流行性感冒的缀合物、组合物和方法
WO2025193784A1 (en) Pharmaceutical formulations for maintaining lean muscle mass during weight loss treatment
US7071232B1 (en) Small molecules that increase the conversion of food to body weight gain
JP2002080397A (ja) 性ホルモン依存性疾患の治療用医薬製剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)